The abstract is read at the publisher; the summary is JClub's.
SARS-CoV-2 and chikungunya virus macrodomain inhibitors repeatedly converge on adenine-anchored scaffolds, defining a structurally confined druggable corridor limited by a permeability–potency tradeoff.
- Why it matters: Translation of catalytic macrodomain inhibition into reliable antiviral efficacy is constrained by how ligand binding requirements affect compound properties and cross-family scaffold portability.
- What they did: The work synthesizes structural, biochemical, and antiviral findings across SARS-CoV-2 and chikungunya virus, mapping conserved active-site subsites and summarizing high-throughput inhibitor discovery patterns.
- The result: It delineates the current boundaries of macrodomain chemical space and the chemical and biological constraints that govern whether catalytic inhibition can predict antiviral performance.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.